期刊文献+

广东人群CYP2C9基因第四外显子多态性研究

The study on the sequence of exon 4 of CYP2C9 gene in Guangdong population
下载PDF
导出
摘要 目的研究广东人群CYP2C9基因第四外显子的多态性。方法PCR扩增50例健康广东人之CYP2C9基因跨越第四外显子的DNA片断,测序后截取完整的第四外显子序列进行blast分析。结果检测的50个广东人的CYP2C9基因第四外显子序列均与GenBank中进入号为AY702706.1的相应序列完全一致。结论广东人群CYP2C9基因第四外显子的基因序列高度保守,无多态性。 Objective To investigate the exon 4 polymorphism of the CYP2C9 gene in Guangdong population. Methods Using the DNA of 50 healthy individuals in Guangdong population as the templates , the DNA fragment containing the complete exon 4 of CYP2C9 gene was amplified by polymerase chain reaction, the PCR products were subjected to direct sequencing and the sequence of exon 4 was drawn to analyze with blast procedure . Results The exon 4 sequences of CYP2C9 gene of the 50 individuals were identical to the published sequence in GenBank (accession number: AY702706.1 ). Conclusion The exon 4 of CYP2C9 gene is highly conserved in Guangdong population and shows no polymorphism.
出处 《广东药学院学报》 CAS 2005年第6期712-714,共3页 Academic Journal of Guangdong College of Pharmacy
基金 广东省自然科学基金(034051) 广东省医学科研基金(A2003347) 广东药学院科研基金(2002272)
关键词 CYP2C9基因 聚合酶链反应 多态性 CYP2C9 gene polymerase chain reaction polymorphism
  • 相关文献

参考文献11

  • 1Goldstein JA, Morais SM. Biochemistry and molecular biology of the human CYP2C subfamily [J]. Pharmacogenetics, 1994,4(6):285.
  • 2Steward DJ, Haining RL, Henne KR, et al. Genetic association between sensitivity to warfarin and expression of CYP2C9 * 3[J]. Pharmacogenetics, 1997,7(5):361.
  • 3Kidd RS, Straughn AB, Meyer MC, et al. Pharmacokinetics of clorpheniramine, phenytoin, glipizide, and nefedipine in an individual homozygous for the CYP2C9 * 3 allele [J]. Pharmacogenetics, 1999,9(1):71.
  • 4Ninomiya H, Mamiya K, Matsuo S, et al. Genetic polymorphism of the CYP2C subfamily and excessive serum phenytoin concentration with central nervous system in toxication [J]. Ther Drug Monit,2000,22(2):230.
  • 5Aithal GP, Day CP, Kesteven PJ, et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications [J]. Lancet,1999,353(9154) :717.
  • 6Martinez C, Blanco G, Ladero JM, et al. Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use [J]. Br J Pharmacol,2004,141(2): 205.
  • 7Leung AY, Chow HC, Kwong YL, et al. Genetic polymorphism in exon 4 of cytochrome P450 CYP2C9 may be associated with warfarin sensitivity in Chinese patients[J]. Blood ,2001,98(8):2 584.
  • 8Schwarz UI. Clinical relevance of genetic polymorphisms in the human CYP2C9 gene [J]. Eur J Clin Invest, 2003,33(Suppl2):23.
  • 9] Rettie AE, Tai G, Veenstra DL, et al. CYP2C9 exon 4 mutations and warfarin dose phenotype in Asians [J]. Blood, 2003,101(7):2 896.
  • 10Zarza J, Hermida J, Montes R, et al. Leu208Val and Ile181Leu variants of cytochrome P450 CYP2C9 are not related to the acenocoumarol dose requirement in a Spanish population[J]. Blood,2002,100(2):734.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部